Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of 4-aminopyridine sustained-release (Fampyra) and acetazolamide (Acemit)
Latest Information Update: 16 May 2020
Price :
$35 *
At a glance
- Drugs Acetazolamide (Primary) ; Fampridine (Primary)
- Indications Ataxia
- Focus Therapeutic Use
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 26 Oct 2016 Status changed from recruiting to completed.
- 25 Sep 2013 New source identified and integrated (German Clinical Trials Register; DRKS00005258).